Table 2 Genetic polymorphisms in association with disease-free and overall survival.

From: Genetic polymorphisms in interleukin-1β (rs1143634) and interleukin-8 (rs4073) are associated with survival after resection of intrahepatic cholangiocarcinoma

Gene, SNP

n, (%)

Disease-free survival (DFS)

Overall survival (OS)

Median DFS, m (95% CI)

Hazard ratio (95% CI)

p†

Median OS, m (95% CI)

Hazard ratio (95% CI)

p†

VEGF + 936 (C > T, rs3025039)

CC

76 (67.9)

13 (5.3–20.7)

1 (reference)

.157

21 (10.0–32.0)

1 (reference)

.674

CT

35 (31.3)

9 (4.0–14.0)

1.425 (0.855–2.375)

20 (12.4–27.6)

1.110 (0.678–1.816)

TT

1 (0.9)

EGF + 61 (A > G, rs4444903)

AA

48 (42.9)

16 (8.2–23.8)

1 (reference)

.669

21 (5.5–36.5)

1 (reference)

.753

AG

64 (57.1)

10 (5.5–14.5)

1.111 (0.676–1.826)

22 (13.8–30.2)

1.077 (0.674–1.721)

GG

0 (0.0)

EGFR-1562 (G > A, rs2227983)

GG

38 (33.9)

10 (5.8–14.2)

1 (reference)

.847

22 (7.6–36.4)

1 (reference)

.262

GA

45 (40.2)

16 (8.2–23.8)

1.013 (0.565–1.815)

28 (6.8–49.2)

1.185 (0.645–2.178)

AA

27 (24.1)

8 (.9–15.1)

1.190 (0.605–2.343)

13 (7.1–18.9)

0.737 (0.426–1.277)

IL-1B +3954 (C > T, rs1143634)

TT

8 (7.1)

24 (n.a.)

1 (reference)

.012

44 (3.9–84.0)

1 (reference)

.034

CT

31 (27.7)

CC

73 (65.2)

9 (5.9–12.1)

1.983 (1.139–3.453)

19 (13.0–25.0)

1.735 (1.043–2.886)

IL-6-174 (G > C, rs1800795)

GG

41 (36.6)

12 (0.0–28.6)

1 (reference)

.413

29 (0.0–69.2)

1 (reference)

.237

GC

53 (47.3)

12 (6.3–17.7)

1.112 (0.644–1.918)

18 (10.3–25.7)

1.537 (0.914–2.587)

CC

16 (14.3)

8 (2.9–13.1)

1.590 (0.781–3.239)

22 (13.1–30.9)

1.465 (0.714–3.004)

IL-8-251 (T > A, rs4073)

TT

33 (29.5)

12 (3.3–20.7)

1 (reference)

.679

40 (14.8–65.2)

1 (reference)

.026

TA

53 (47.3)

12 (7.7–16.3)

1.203 (0.674–2.149)

13 (2.7–23.3)

2.001 (1.144–3.498)

AA

20 (17.9)

8 (0.2–15.8)

1.339 (0.661–2.714)

32 (6.3–57.7)

1.177 (0.566–2.445)

IL-10-592 (T > G, rs1800872)

TT

5 (4.5)

12 (6.9–17.1)

1 (reference)

.380

19 (11.9–26.1)

1 (reference)

.928

TG

53 (47.3)

GG

54 (48.2)

10 (5.6–14.4)

1.239 (0.758–2.023)

22 (15.9–28.1)

0.979 (0.616–1.557)

CXCR1 + 860(Ex2) (C > G, rs2234671)

CC

102 (91.1)

12 (8.6–15.4)

1 (reference)

.638

20 (16.3–23.7)

1 (reference)

.662

CG

10 (8.9)

7 (1.9–12.1)

0.789 (0.286–2.175)

25 (0.0–82.8)

0.817 (0.353–1.892)

GG

0 (0.0)

HIF1α-1772 (C > T, rs11549465)

CC

88 (78.6)

11 (8.0–14.0)

1 (reference)

.461

19 (11.3–26.6)

1 (reference)

.676

CT

23 (20.5)

18 (8.1–27.9)

0.804 (0.443–1.459)

28 (5.0–51.0)

0.889 (0.507–1.558)

TT

0 (0.0)

PTGS2 (COX2) + 8473 (A > G, rs5275)

AA

49 (43.8)

12 (9.2–14.8)

1 (reference)

.669

20 (8.9–31.0)

1 (reference)

.630

AG

48 (42.9)

12 (6.3–17.7)

0.988 (0.588–1.661)

25 (11.9–38.1)

0.891 (0.547–1.451)

GG

12 (10.0)

18 (2.1–33.9)

0.632 (0.283–1.650)

29 (0.0–62.9)

0.694 (0.307–1.567)

PTGS2 (COX2)-765 (G > C, rs20417)

GG

81 (72.3)

11 (6.9–15.1)

1 (reference)

.993

22 (12.9–31.1)

1 (reference)

.360

GC

25 (22.3)

13 (3.8–22.3)

0.998 (0.578–1.722)

29 (2.6–55.4)

0.783 (0.459–1.334)

CC

4 (3.5)

  1. Based on Cox proportional hazards model, for DFS including: Blood transfusions, microvascular invasion, lymphovascular invasion, lymph node positivity, UICC stage. For OS including: Alkaline phosphatase, hemoglobin, C-reactive protein, blood transfusions, microvascular invasion, lymphovascular invasion, lymph node positivity, UICC stage, comprehensive complication index and hospitalization. Also see Supplementary Table 2 and 3.
  2. n.a. estimates not reached, CI confidence interval, CXCR chemokine receptor, EGF epidermal growth factor, EGFR epidermal growth factor receptor, HIF-1α hypoxia-inducing factor alpha, IL interleukin, PTGS prostaglandin-endoperoxide synthase 2, SNP single-nucleotide polymorphism, VEGF vascular endothelial growth factor, iCCA intrahepatic cholangiocarcinoma.
  3. †Based on log-rank test.
  4. $Significances given for the T/A vs. T/T groups and for the “2 unfavorable” vs. “0 unfavorable” groups.
  5. Significant values are in bold.
Back to article page